I. AMENDMENTS TO THE CLAIMS

This Listing Claims shall replace all prior versions, and listings, of the claims in the application.

Listing of Claims

Claim 1. (Original): A transdermal delivery device comprising: a drug containing layer comprising an effective amount of an opioid agonist and a plurality of microspheres dispersed in the drug containing layer, the microspheres comprising an opioid antagonist and being visually indiscernible in the drug containing layer.

Claim 2. (Currently Amended): The transdermal delivery device of claim 1, wherein the microspheres have a mean diameter size of from about 1 to about 500 microns µm in diameter.

Claim 3. (Currently Amended): A transdermal delivery device comprising: a drug containing layer comprising an effective amount of an opioid agonist and a plurality of microspheres dispersed in the drug containing layer, the microspheres comprising an opioid antagonist and <u>having in</u> a mean size of from about 1 to about 500 microns.

Claim 4. (Currently Amended): The transdermal delivery device of claim 3, wherein the microspheres are in a have the mean diameter size of from about 1 to about 300 microns µm in diameter.

Claim 5. (Currently Amended): The transdermal delivery device of claim 1, wherein the plurality of microspheres comprise the opioid antagonist dispersed in a polymeric matrix.

Claim 6. (Currently Amended): The transdermal delivery device of claim 1, wherein the microspheres further comprise a polymer selected from the group consisting of polyesters, polyethers, poly(orthoesters), polysaccharides, cyclodextrins, chitosans, poly

Application No. 10/584,816 Amd. Dated April 8, 2010 Reply to Office Action Mailed on March 9, 2010

,

 $(\Sigma$ -caprolactones) poly(e-caprolactones), polyanhydrides polyantydrides, albumin, blends, and copolymers thereof and mixtures thereof.

Claim 7. (Currently Amended): The transdermal delivery device of claim 1, wherein the microspheres consist essentially of the opioid antagonist and a polymer selected from the group consisting of polyesters, polyethers, poly(orthoesters), polysaccharides, cyclodextrins, chitosans, poly (Σ -caprolactones) poly(e-caprolactones), polyanhydrides, albumin, blends, and copolymers and mixtures thereof.

Claim 8. (Previously Presented): The transdermal delivery device of claim 1, wherein the microspheres consist essentially of the opioid antagonist dispersed in a polymeric matrix.

Claim 9. (Currently Amended): The transdermal delivery device of claim 1, wherein the microspheres are in have a mean diameter size of from about 300 to about 500 microns in diameter.

Claim 10. (Currently Amended): The transdermal delivery device of claim 1, wherein the microspheres are in have a mean diameter size of from about 200 to about 500 microns in diameter.

Claim 11. (Currently Amended): The transdermal delivery device of claim 1, wherein the microspheres are in <u>have</u> a mean <u>diameter</u> size of from about 125 to about 200 microns in <u>diameter</u>.

Claim 12. (Currently Amended): The transdermal delivery device of claim 1, wherein the opioid antagonist is not releasable when the transdermal delivery device is applied topically intact to a skin of a human patient, and is becomes releasable if the transdermal delivery device is chewed, soaked, punctured, torn, or subjected to any other treatment which disrupts the integrity of the microspheres.

Application No. 10/584,816 Amd. Dated April 8, 2010 Reply to Office Action Mailed on March 9, 2010

Claim 13. (Currently Amended): The transdermal delivery device of <u>claim 12 elaim 1</u>, wherein the effect of the opioid agonist is at least partially blocked <u>by the opioid antagonist</u> when the <u>delivery device is chewed</u>, <u>crushed or dissolved in a solvent</u>, <u>or subject to any other treatment which disrupts</u> the integrity of the microspheres <u>is disrupted</u>, and <u>the disrupted microspheres are</u> administered orally, intranasally, parenterally or sublingually.

Claims 14-17. (Cancelled)

Claim 18. (Currently Amended): The transdermal delivery device of claim 1, wherein the opioid antagonist is naltrexone or a pharmaceutically acceptable addition salt thereof.

Claim 19. (Currently Amended): The transdermal delivery device of claim 1, wherein the microspheres are in have a mean diameter size of from about 50 to about 100 microns in diameter.

Claim 20. (Cancelled)

Claim 21. (Previously Presented): The transdermal delivery device of claim 1, wherein the drug containing layer is a matrix layer.

Claim 22. (Currently Amended): The transdermal delivery device of claim 21, where the matrix comprises a material selected from the group consisting of polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethylacrylate copolymers, ethylenevinyl acetate copolymers, silicones, rubber, rubber- like synthetic homo-, co- or block polymers, polyacrylic esters and the copolymers thereof, polyurethanes, polyisobutylene, chlorinated polyethylene, polyvinylchloride, vinyl chloride-vinyl acetate copolymer, polymethacrylate polymer (hydrogel), polyvinylidene chloride, poly(ethylene terephthalate), ethylene-vinyl alcohol copolymer, ethylene vinyloxyethanol copolymer, silicone copolymers s (e.g., silicone copolymers such as polysiloxane-polymethacrylate

Application No. 10/584,816 Amd. Dated April 8, 2010 Reply to Office Action Mailed on March 9, 2010

copolymers), cellulose polymers (e.g., ethyl cellulose, and cellulose esters), polycarbonates, polytetrafluoroethylene and mixtures thereof.

Claim 23. (Currently Amended): The transdermal delivery device of claim 5, where the matrix comprises a polymer is selected from the group consisting of silicone copolymers, silicone polymers that are cross-linkable, copolymers having dimethyl and/or dimethylvinyl siloxane units which can be crosslinked, block copolymers based on styrene and 1,3-dienes, polyisobutylenes, and polymers based on acrylate and/or methacrylate.

Claims 24-30. (Cancelled)

Claim 31. (Currently Amended): The transdermal delivery device of claim 1, wherein the microspheres are in have a mean diameter size of from about 1 to about 200 microns in diameter.

Claim 32. (Currently Amended): The transdermal delivery device of claim 1, wherein the microspheres are in have a mean size of diameter of from about 1 to about 100 microns in diameter.

Claim 33-36. (Cancelled)